Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associated SCC
Condition: Recessive Dystrophic Epidermolysis Bullosa Interventions: Drug: Rigosertib Sodium; Other: Quality-of-Life Assessment Sponsors: Thomas Jefferson University; Onconova Therapeutics, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials